Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7B35

MST3 in complex with compound MRIA13

7B35 の概要
エントリーDOI10.2210/pdb7b35/pdb
分子名称Serine/threonine-protein kinase 24, 8-[(5-azanyl-1,3-dioxan-2-yl)methyl]-6-[2-chloranyl-4-(3-methoxy-6-methyl-pyridin-2-yl)phenyl]-2-(methylamino)pyrido[2,3-d]pyrimidin-7-one (3 entities in total)
機能のキーワードkinase inhibitors, structure-based drug design, sik2 inhibitor, structural genomics consortium, sgc, transferase
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計70165.26
構造登録者
Tesch, R.,Rak, M.,Joerger, A.C.,Knapp, S.,Structural Genomics Consortium (SGC) (登録日: 2020-11-28, 公開日: 2020-12-16, 最終更新日: 2024-01-31)
主引用文献Tesch, R.,Rak, M.,Raab, M.,Berger, L.M.,Kronenberger, T.,Joerger, A.C.,Berger, B.T.,Abdi, I.,Hanke, T.,Poso, A.,Strebhardt, K.,Sanhaji, M.,Knapp, S.
Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
J.Med.Chem., 64:8142-8160, 2021
Cited by
PubMed Abstract: Salt-inducible kinases (SIKs) are key metabolic regulators. The imbalance in SIK function is associated with the development of diverse cancers, including breast, gastric, and ovarian cancers. Chemical tools to clarify the roles of SIK in different diseases are, however, sparse and are generally characterized by poor kinome-wide selectivity. Here, we have adapted the pyrido[2,3-]pyrimidin-7-one-based p21-activated kinase (PAK) inhibitor G-5555 for the targeting of SIK, by exploiting differences in the back-pocket region of these kinases. Optimization was supported by high-resolution crystal structures of G-5555 bound to the known off-targets, MST3 and MST4, leading to a chemical probe, MRIA9, with dual SIK/PAK activity and excellent selectivity over other kinases. Furthermore, we show that MRIA9 sensitizes ovarian cancer cells to treatment with the mitotic agent paclitaxel, confirming earlier data from genetic knockdown studies and suggesting a combination therapy with SIK inhibitors and paclitaxel for the treatment of paclitaxel-resistant ovarian cancer.
PubMed: 34086472
DOI: 10.1021/acs.jmedchem.0c02144
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.40005138292 Å)
構造検証レポート
Validation report summary of 7b35
検証レポート(詳細版)ダウンロードをダウンロード

250059

件を2026-03-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon